CLINICAL TRIAL

white wine for Unspecified Adult Solid Tumor, Protocol Specific

Waitlist Available · 18+ · All Sexes · Rochester, MN

This study is evaluating whether white wine is more effective than a nutritional supplement in improving appetite in patients with cancer.

See full description

About the trial for Unspecified Adult Solid Tumor, Protocol Specific

Treatment Groups

This trial involves 2 different treatments. White Wine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
questionnaire administration
OTHER
white wine
DIETARYSUPPLEMENT
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
questionnaire administration
OTHER
therapeutic nutritional supplementation
OTHER

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
white wine
2016
N/A
~40

Eligibility

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patient perceives loss of appetite and/or weight as a problem; NOTE: Documentation not necessary
Willingness to abstain completely from alcohol for 4 weeks, except as prescribed in this trial; NOTE: Patients assigned to the non-wine nutritional supplement (Arm B) must be willing to abstain from wine and other alcoholic beverages for 3-4 weeks; Patients assigned to the white wine (Arm A) are allowed to take a nutritional supplement, such as Ensure or Boost if they choose to
Ability to complete questionnaire(s) by themselves or with assistance
Incurable, invasive malignancy
No prior or current history of alcoholism
Alert and mentally competent
Physician estimates that patient has lost >= 5 pounds (2.3 kg) in weight =< 2 months (excluding peri-operative weight loss; documented weight loss not required) and/or have estimated caloric intake of < 20 cal/kg daily (no further documentation necessary other than an affirmative answer to this statement)
Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Every 6 months for 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Every 6 months for 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether white wine will improve 1 primary outcome and 4 secondary outcomes in patients with Unspecified Adult Solid Tumor, Protocol Specific. Measurement will happen over the course of Prior to study intervention and then weekly.

Patient-reported quality of life (QOL) as measured by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) appetite scale
PRIOR TO STUDY INTERVENTION AND THEN WEEKLY
Difference in the percentage of patients who report an improvement in their appetite over the intervention period
FIRST 3 WEEKS
Incidence of study intervention-related toxicity
PRIOR TO REGISTRATION AND AT WEEK 3-4
Overall survival
EVERY 6 MONTHS FOR 2 YEARS
Differences in the percentage of patients who manifest weight stability, defined as weight gain of at least 5% of baseline
AT ONE MONTH

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get unspecified adult solid tumor, protocol specific a year in the United States?

The annual frequency of sarcoma is more than 4-fold that of all cancer among the general population but this may be because sarcoma is more likely than all cancer to metastasize and therefore appear as an unspecified adult solid tumor.

Anonymous Patient Answer

What is unspecified adult solid tumor, protocol specific?

"Unexplained adult solid tumor" may be in fact a nonspecific presentation of any type of malignancy. In the era of modern chemotherapy, these tumors may be cured or at least controlled, and treatment should be initiated or postponed.

Anonymous Patient Answer

Can unspecified adult solid tumor, protocol specific be cured?

Only 7% of the cohort developed secondary cancer. The median DMFI and MSS is 14.5% and 6.5, respectively. The median survival was 37.0 months for our cohort. While local recurrence was high, the risk of secondary cancers may not be associated with the treatment delivered to the tumor.

Anonymous Patient Answer

What causes unspecified adult solid tumor, protocol specific?

In both small cell and squamous cell cancers the most important environmental carcinogens and risk factors include: exposure to ionizing radiation, tobacco smoking, second-hand smoke, asbestos, talc, welding, solvents, pesticide poisoning, and exposure to dioxins and furans at levels found in contaminated drinking water supplies.\n

Anonymous Patient Answer

What are common treatments for unspecified adult solid tumor, protocol specific?

There is little consistency in treatment of solid tumors between protocols. Therefore, the quality of the care is low. The present study indicates that there is an urgent need for better defined protocols for the treatment of specific forms of solid tumors.

Anonymous Patient Answer

What are the signs of unspecified adult solid tumor, protocol specific?

The signs of unspecified adult solid tumor in the P-P system should be considered a surrogate of malignancy. These include coughing blood or mucus, pleural effusions, haemoptysis, and weight loss>3.5 kg (4 pounds) per month.

Anonymous Patient Answer

Is white wine typically used in combination with any other treatments?

Both the European Food Safety Authority and the U.S. Food and Drug Administration had concluded that no clear evidence existed to support or rule out any clinically significant interaction between wine and other commonly used medications, with the exception of some drugs and wine when taken in small amounts as an aid in digestion or to counteract the hangover after a meal or for hangover relief. Additional in vitro studies are warranted to further substantiate these findings.

Anonymous Patient Answer

What is the latest research for unspecified adult solid tumor, protocol specific?

The number of published studies with information for unspecified adult solid tumor, protocol specific has increased between 2001 and 2010. This pattern of increasing publication may reflect methodological developments, which include clinical trials with more participants than have been typically reported, increasing use of electronic databases, and use of more specific and accurate diagnostic criteria. The number of published studies continues to decline. Further research to improve the quality of available data is needed.

Anonymous Patient Answer

What is the primary cause of unspecified adult solid tumor, protocol specific?

Some common causes of SOT are cancer of unknown primary site, tumor of unknown primary site, metastatic solid tumor, infiltrative neoplasm of unknown primary site, metastatic unknown primary tumor, and primary lymphoma.

Anonymous Patient Answer

Who should consider clinical trials for unspecified adult solid tumor, protocol specific?

Clinical Trial Participation Rates for Solid Tumor Inclusion in Protocols that require a Breslow >5 mm was significantly lower in women than in men. In all solid tumor cases, there were no statistically significant differences in trial participation rates by race or ethnicity. Clinically informed decision making is supported by the results of this study. The findings for trials specifically targeting solid tumors must be interpreted in the context of the overall participation in trials across all solid tumors and in trials specifically targeting solid tumors for women. Findings from a recent study of this study suggest that the potential savings in the cost to the health care system by avoiding unnecessary trials for solid tumors in women may outweigh the potential risks of enrolling women in clinical trials with uncertain risks or benefits.

Anonymous Patient Answer

Have there been other clinical trials involving white wine?

Data from a recent study reported here are limited by the small number of publications reporting such clinical trials in the relevant period period. Data from a recent study of this study may be of importance for clinicians who wish to learn more about the use of wine and have no access to publications reporting clinical trials on this topic.

Anonymous Patient Answer

How does white wine work?

The findings from this study imply that the effects of wine on colonic microflora are not related to the level of bioavailable phenolic compounds that wine contains. Further studies should investigate whether the bioactivity of wine molecules is in fact related to alterations in the gut microflora, the host gut microbiome, or a combination of these two.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Unspecified Adult Solid Tumor, Protocol Specific by sharing your contact details with the study coordinator.